Targeting the Vascular Endothelium in the Treatment of COVID-19.

Suvorava, Tatsiana; Kaesemeyer, Wayne

Suvorava, Tatsiana; Kaesemeyer, Wayne.

Suvorava T; Institute of Pharmacology and Clinical Pharmacology, University Hospital, Duesseldorf, Germany; and.
Kaesemeyer W; Augusta Hypertension PC, Chapel Hill, North Carolina.

J Cardiovasc Pharmacol ; 77(1): 1-3, 2021 01 01.

Article in English | MEDLINE | ID: covidwho-880843

ABSTRACT

ABSTRACT

ABSTRACT The involvement of the vascular endothelium in the complications of coronavirus disease 2019 is now recognized. Chief among these are pulmonary endotheliitis, cytokine storm, endotoxic shock, and cardiovascular collapse. This Perspectives article is focused on therapeutical strategies to reduce the risk of these complications by targeting the vascular endothelium as a part of the overall treatment of coronavirus disease 2019.

Subject(s)

COVID-19/metabolism; Cytokine Release Syndrome/metabolism; Drug Delivery Systems/methods; Endothelium, Vascular/metabolism; Angiotensin II/administration & dosage; Angiotensin-Converting Enzyme 2/antagonists & inhibitors; Angiotensin-Converting Enzyme 2/metabolism; Cytokine Release Syndrome/drug therapy; Drug Delivery Systems/trends; Endothelium, Vascular/drug effects; Humans; COVID-19 Drug Treatment

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Endothelium, Vascular / Drug Delivery Systems / Cytokine Release Syndrome / COVID-19 Type of study: Prognostic study Limits: Humans Language: English Journal: J Cardiovasc Pharmacol Year: 2021 Document Type: Article

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google